

BOARD PAPER - NHS ENGLAND

Title: Report of the Specialised Services Commissioning Committee held on 3 November 2015
Lead Director: Noel Gordon, Non-Executive Director and Committee Chair
Purpose of Paper: <ul style="list-style-type: none">To update the Board of the meeting of the Specialised Services Commissioning Committee on 3 November 2016.
The Board is invited to: <ul style="list-style-type: none">Note the content of the report.

REPORT TO THE BOARD FROM: Specialised Services Commissioning Committee

COMMITTEE CHAIR: Noel Gordon

DATE(S) OF COMMITTEE MEETING:

1.0 ITEMS FOR THE BOARD'S INFORMATION AND ASSURANCE

- 2.1 The Committee were updated on the latest contracting and financial position at Month 6 and were assured that discussions were ongoing with the South region to recover the additional forecast deficit, noting that discussions had already taken place with the other regions.
- 2.2 The Committee were advised that the Hepatitis C NICE Technology Appraisal would be published later in December and noted the role of Operational Delivery Networks in supporting the delivery of new treatments.
- 2.3 The Committee noted the projected growth in spend on drugs and devices, The Committee also noted the work programme that is underway to ensure maximum value from the specialised spend on drugs and devices.
- 2.4 The Committee agreed the overarching approach to the Prioritisation Framework for 2016/17, including the next steps to determine whether a new prioritisation methodology would be appropriate for 2016/17. It was agreed that the Prioritisation Framework should return to the next meeting of the Committee for a final decision on the preferred framework, which will subsequently go into a process of consultation.
- 2.5 The Committee discussed the strategic reform agenda for specialised services to govern its strategic direction through to at least 2018. The Committee recognised that the reform agenda will evolve progressively over 2016 as it incorporates the implications of the Accelerated Access Review (AAR) and other external considerations. It was agreed that the next version of the reform agenda would be discussed more fully at the next meeting of the Committee.
- 2.6 The Committee noted that the Specialised Commissioning Oversight Group had approved the in-year service development of the treatment of Severe Refractory Uveitis.

3.0 RECOMMENDATION

- 3.1 The Board is invited to note the content of the report

Author: Noel Gordon, Non-Executive Director
Date: January 2016